DK4031143T3 - Terapeutiske konjugater - Google Patents
Terapeutiske konjugaterInfo
- Publication number
- DK4031143T3 DK4031143T3 DK20865745.2T DK20865745T DK4031143T3 DK 4031143 T3 DK4031143 T3 DK 4031143T3 DK 20865745 T DK20865745 T DK 20865745T DK 4031143 T3 DK4031143 T3 DK 4031143T3
- Authority
- DK
- Denmark
- Prior art keywords
- therapeutic conjugates
- conjugates
- therapeutic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962902554P | 2019-09-19 | 2019-09-19 | |
| US202063078055P | 2020-09-14 | 2020-09-14 | |
| PCT/US2020/051491 WO2021055747A1 (en) | 2019-09-19 | 2020-09-18 | Therapeutic conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK4031143T3 true DK4031143T3 (da) | 2025-10-13 |
Family
ID=74883745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20865745.2T DK4031143T3 (da) | 2019-09-19 | 2020-09-18 | Terapeutiske konjugater |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US20220387603A1 (da) |
| EP (1) | EP4031143B1 (da) |
| JP (1) | JP7810640B2 (da) |
| KR (1) | KR20220079866A (da) |
| CN (2) | CN120789282A (da) |
| AU (1) | AU2020349543A1 (da) |
| BR (1) | BR112022005026A2 (da) |
| CA (1) | CA3154079A1 (da) |
| CL (1) | CL2022000665A1 (da) |
| CO (1) | CO2022003703A2 (da) |
| DK (1) | DK4031143T3 (da) |
| ES (1) | ES3043134T3 (da) |
| IL (1) | IL291486B1 (da) |
| MX (1) | MX2022003217A (da) |
| PE (1) | PE20230091A1 (da) |
| PH (1) | PH12022550494A1 (da) |
| TW (1) | TWI870468B (da) |
| WO (1) | WO2021055747A1 (da) |
| ZA (1) | ZA202203201B (da) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021055747A1 (en) | 2019-09-19 | 2021-03-25 | Totus Medicines Inc. | Therapeutic conjugates |
| WO2022198024A1 (en) * | 2021-03-18 | 2022-09-22 | Totus Medicines Inc. | Therapeutic conjugates |
| WO2023183936A2 (en) * | 2022-03-24 | 2023-09-28 | Totus Medicines Inc. | Combination therapy of a pi3k inhibitor and kras inhibitor and methods of use thereof |
| JP2025509950A (ja) | 2022-03-24 | 2025-04-11 | トータス メディスンズ インコーポレイテッド | Pi3k阻害剤の結晶形態及び塩ならびにその製造方法及びその使用方法 |
| IL315733A (en) | 2022-04-08 | 2024-11-01 | SHY Therapeutics LLC | Compounds that Interact with RAS Superfamily Proteins for the Treatment of Cancer, Inflammatory, Basoplastic, and Fibrotic Diseases |
| EP4604963A2 (en) * | 2022-10-18 | 2025-08-27 | Totus Medicines Inc. | Covalent inhibitors of wild-type and mutant pi3k and method of uses thereof |
| WO2024220380A2 (en) * | 2023-04-16 | 2024-10-24 | Totus Medicines Inc. | Pi3k assays and probe compounds therein |
| KR20260005985A (ko) | 2023-05-05 | 2026-01-12 | 일라이 릴리 앤드 캄파니 | Er+ 유방암을 갖는 대상체에서 중추 신경계 (cns) 전이를 치료 및 예방하는 데 사용하기 위한 임루네스트란트 또는 그의 염 |
| CN117126164B (zh) * | 2023-08-30 | 2024-09-27 | 山东轩硕医药科技有限公司 | 一种吡咯并三嗪类化合物,其制备方法及用途 |
| WO2025072796A1 (en) * | 2023-09-27 | 2025-04-03 | Totus Medicines Inc. | Pharmaceutical compositions and methods of use thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585245A (en) | 1994-04-22 | 1996-12-17 | California Institute Of Technology | Ubiquitin-based split protein sensor |
| US6342345B1 (en) | 1997-04-02 | 2002-01-29 | The Board Of Trustees Of The Leland Stanford Junior University | Detection of molecular interactions by reporter subunit complementation |
| US6982265B1 (en) | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| US7306631B2 (en) | 2004-03-30 | 2007-12-11 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
| US7880004B2 (en) | 2005-09-15 | 2011-02-01 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| CA2695989A1 (en) | 2007-08-10 | 2009-02-19 | Glaxosmithkline Llc | Certain nitrogen containing bicyclic chemical entities for treating viral infections |
| CA2730930C (en) * | 2008-07-16 | 2015-01-13 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
| US20100204265A1 (en) | 2009-02-09 | 2010-08-12 | Genelabs Technologies, Inc. | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections |
| JP2013504325A (ja) * | 2009-09-09 | 2013-02-07 | アビラ セラピューティクス, インコーポレイテッド | Pi3キナーゼインヒビターおよびその使用 |
| US9073927B2 (en) | 2010-01-22 | 2015-07-07 | Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii | Inhibitors of PI3 kinase |
| WO2011141713A1 (en) | 2010-05-13 | 2011-11-17 | Centro Nacional De Investigaciones Oncologicas (Cnio) | New bicyclic compounds as pi3-k and mtor inhibitors |
| MX2012013824A (es) | 2010-05-28 | 2013-03-12 | Biocryst Pharm Inc | Compuestos heterociclicos como inhibidores de cinasa janus. |
| US20120231963A1 (en) | 2011-03-10 | 2012-09-13 | Raybiotech, Inc, | Biotin-label-based antibody array for high-content profiling of protein expression |
| ES2770550T3 (es) * | 2011-05-17 | 2020-07-02 | Univ California | Inhibidores de quinasa |
| EP2524918A1 (en) | 2011-05-19 | 2012-11-21 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyrazines derivates as kinase inhibitors |
| US9724352B2 (en) * | 2012-05-31 | 2017-08-08 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof |
| CN103450204B (zh) | 2012-05-31 | 2016-08-17 | 中国科学院上海药物研究所 | 吡咯[2,1-f][1,2,4]并三嗪类化合物,其制备方法及用途 |
| CN102675323B (zh) | 2012-06-01 | 2014-04-09 | 南京药石药物研发有限公司 | 吡咯并[2,1-f][1,2,4]三嗪衍生物及其抗肿瘤用途 |
| EP3157920B1 (en) | 2014-06-17 | 2019-08-07 | Chiesi Farmaceutici S.p.A. | Indolizine derivatives as phosphoinositide 3-kinases inhibitors |
| KR20170060042A (ko) * | 2014-09-13 | 2017-05-31 | 노파르티스 아게 | Alk 억제제의 조합 요법 |
| WO2017004134A1 (en) | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| CN109111447A (zh) * | 2017-06-23 | 2019-01-01 | 中国科学院上海药物研究所 | 7-位取代吡咯并三嗪类化合物或其药学上可用的盐,及其制备方法和用途 |
| WO2019027765A1 (en) | 2017-08-02 | 2019-02-07 | Northwestern University | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS AND USES THEREOF |
| WO2019113523A1 (en) | 2017-12-08 | 2019-06-13 | Ashok Bajji | Compounds and therapeutic uses thereof |
| CN109081905A (zh) | 2018-08-03 | 2018-12-25 | 浩力森涂料(上海)有限公司 | 水性环氧固化剂及其制备方法 |
| US20220054496A1 (en) | 2018-09-13 | 2022-02-24 | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncologicas Carlos III (F.S. | Modulation of trf1 for brain cancer treatment |
| WO2020243457A1 (en) | 2019-05-29 | 2020-12-03 | Viogen Biosciences, Llc | Compounds and therapeutic uses thereof |
| WO2021055747A1 (en) | 2019-09-19 | 2021-03-25 | Totus Medicines Inc. | Therapeutic conjugates |
| KR20230035036A (ko) | 2020-06-05 | 2023-03-10 | 모나쉬 유니버시티 | 이중 키나제-브로모도메인 억제제 |
| WO2022031952A2 (en) | 2020-08-07 | 2022-02-10 | City Of Hope | Treatments for cancers having kras mutations |
| WO2022198024A1 (en) | 2021-03-18 | 2022-09-22 | Totus Medicines Inc. | Therapeutic conjugates |
| WO2023183936A2 (en) | 2022-03-24 | 2023-09-28 | Totus Medicines Inc. | Combination therapy of a pi3k inhibitor and kras inhibitor and methods of use thereof |
| JP2025509950A (ja) | 2022-03-24 | 2025-04-11 | トータス メディスンズ インコーポレイテッド | Pi3k阻害剤の結晶形態及び塩ならびにその製造方法及びその使用方法 |
-
2020
- 2020-09-18 WO PCT/US2020/051491 patent/WO2021055747A1/en not_active Ceased
- 2020-09-18 JP JP2022516684A patent/JP7810640B2/ja active Active
- 2020-09-18 CA CA3154079A patent/CA3154079A1/en active Pending
- 2020-09-18 CN CN202510512926.7A patent/CN120789282A/zh active Pending
- 2020-09-18 EP EP20865745.2A patent/EP4031143B1/en active Active
- 2020-09-18 BR BR112022005026A patent/BR112022005026A2/pt not_active IP Right Cessation
- 2020-09-18 MX MX2022003217A patent/MX2022003217A/es unknown
- 2020-09-18 AU AU2020349543A patent/AU2020349543A1/en active Pending
- 2020-09-18 PE PE2022000435A patent/PE20230091A1/es unknown
- 2020-09-18 PH PH1/2022/550494A patent/PH12022550494A1/en unknown
- 2020-09-18 ES ES20865745T patent/ES3043134T3/es active Active
- 2020-09-18 DK DK20865745.2T patent/DK4031143T3/da active
- 2020-09-18 KR KR1020227012813A patent/KR20220079866A/ko active Pending
- 2020-09-18 CN CN202080074001.4A patent/CN114599366B/zh active Active
- 2020-09-18 TW TW109132462A patent/TWI870468B/zh active
- 2020-09-18 US US17/642,945 patent/US20220387603A1/en active Pending
-
2022
- 2022-03-14 US US17/694,592 patent/US11484597B2/en active Active
- 2022-03-17 ZA ZA2022/03201A patent/ZA202203201B/en unknown
- 2022-03-18 CL CL2022000665A patent/CL2022000665A1/es unknown
- 2022-03-18 IL IL291486A patent/IL291486B1/en unknown
- 2022-03-28 CO CONC2022/0003703A patent/CO2022003703A2/es unknown
- 2022-09-28 US US17/955,182 patent/US12029791B2/en active Active
-
2024
- 2024-07-03 US US18/763,741 patent/US20240366771A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PH12022550494A1 (en) | 2023-02-27 |
| JP2022548135A (ja) | 2022-11-16 |
| US20240366771A1 (en) | 2024-11-07 |
| CN114599366A (zh) | 2022-06-07 |
| TW202126307A (zh) | 2021-07-16 |
| ES3043134T3 (en) | 2025-11-24 |
| ZA202203201B (en) | 2023-11-29 |
| EP4031143B1 (en) | 2025-07-30 |
| CN120789282A (zh) | 2025-10-17 |
| US11484597B2 (en) | 2022-11-01 |
| IL291486A (en) | 2022-05-01 |
| CL2022000665A1 (es) | 2022-10-28 |
| MX2022003217A (es) | 2022-06-29 |
| US20220211855A1 (en) | 2022-07-07 |
| US20230096658A1 (en) | 2023-03-30 |
| CA3154079A1 (en) | 2021-03-25 |
| US12029791B2 (en) | 2024-07-09 |
| IL291486B1 (en) | 2026-03-01 |
| JP7810640B2 (ja) | 2026-02-03 |
| CN114599366B (zh) | 2025-05-09 |
| TWI870468B (zh) | 2025-01-21 |
| AU2020349543A1 (en) | 2022-03-24 |
| PE20230091A1 (es) | 2023-01-16 |
| US20220387603A1 (en) | 2022-12-08 |
| WO2021055747A1 (en) | 2021-03-25 |
| EP4031143A4 (en) | 2023-11-01 |
| EP4031143A1 (en) | 2022-07-27 |
| BR112022005026A2 (pt) | 2022-06-21 |
| KR20220079866A (ko) | 2022-06-14 |
| CO2022003703A2 (es) | 2022-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286291A (en) | Compounds and conjugates thereof | |
| IL291486A (en) | Therapeutic conjugates | |
| EP4056220A4 (en) | CATHETER | |
| EP3807644A4 (en) | ANTIBODY-OLIGONUCLEOTIDE CONJUGATES | |
| EP3873486A4 (en) | Bivalent targeted conjugates | |
| DK3579883T3 (da) | Pyrrolobenzodiazepin-antistofkonjugater | |
| LT3544636T (lt) | Pirolobenzodiazepino-antikūno konjugatai | |
| CY1125598T1 (el) | Συζευγματα πυρρολοβενζοδιαζεπινης | |
| DK3870234T3 (da) | Antistoflægemiddelkonjugater omfattende ecteinascidinderivater | |
| EP3735463A4 (en) | Cytotoxicity-inducing therapeutic agent | |
| EP3976158A4 (en) | Catheter | |
| EP3718588C0 (en) | CATHETER | |
| DK3668874T3 (da) | Pyrrolobenzodiazepin-konjugater | |
| DK3768830T5 (da) | Cancerterapi | |
| EP4308121A4 (en) | THERAPEUTIC CONJUGATES | |
| IL282330A (en) | Therapeutic compounds | |
| EP4026582A4 (en) | CATHETER | |
| EP3860585A4 (en) | Therapeutic compositions | |
| DK4217398T3 (da) | Anti-c-met-antistof-lægemiddelkonjugater | |
| MA55132A (fr) | Conjugués bi-spécifiques | |
| EP4013440A4 (en) | THERAPEUTIC PEPTIDES | |
| EP3986939A4 (en) | TWO-DRUG ANTIBODY-DRUG CONJUGATE | |
| EP3999592A4 (en) | Theranostic conjugates | |
| EP3927328A4 (en) | INHALABLE THERAPEUTIC AGENT | |
| EP4333898A4 (en) | PEPTIDE-LIPID CONJUGATES |